Navigation Links


Vion at Biology News

Vion at Biology Products

NanoMate ™ 100 with ESI Chip Technology from Advion Biosciences, Inc.

Description:Advion's NanoMate 100 robotic system and disposable ESI Chip allow users to take full advantage of the capabilities of electrospray mass spectrometers for life science applications. Integrating the NanoMate with MS allows users to either speed analysis for increased throughput for small molecule and peptide mapping applications, or long acquisition times for proteomics and metabolism applications...
Company:Advion Biosciences, Inc.
Vion at Biology Technology
Vion at Medicine News
Vion at Medicine Products
Vion at Medicine Technology

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

NEW HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- VionPharmaceuticals, Inc. announced that it presented clinical data ina poster session at the 12th Congress of the European HematologyAssociation (EHA) Meeting in Vienna, Austria on its lead anticanceragent Cloretazine(R) (VNP40101M) as a single agent in amulti-center international Phase II clinical trial in a subset ofelderly pat...

Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VIONPHARMACEUTICALS, INC. announced that it presented updated clinicaldata in a poster session at the 43rd Annual Meeting of The AmericanSociety of Clinical Oncology (ASCO) on its lead anticancer agentCloretazine(R) (VNP40101M) as a single agent in a Phase II trial inpatients with relapsed or refractory small cell lung cancer....

PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week

Nuvion Antibody Led to a Sustained Response and Remission inFollow-up to Phase 1 and Phase 1/2 studies and Was AdequatelyTolerated in Patients with IV Steroid-Refractory Ulcerative Colitis FREMONT, Calif., May 22, 2007 /PRNewswire-FirstCall/ -- Datapresented at the Digestive Disease Week (DDW) meeting this week inWashington D.C. by Dr. William Sandborn from the Mayo Clinicsuggest that Nuv...

Vion Presents Data on Cloretazine (VNP40101M) at the 100th Annual Meeting of the American Association of Cancer Research (AACR)

NEW HAVEN, Conn., April 13, 2007 /PRNewswire-FirstCall/ -- VIONPHARMACEUTICALS, INC. announced today that data on its leadanticancer agent Cloretazine(R) (VNP40101M) will be presented inposters at the 100th Annual Meeting of the American Association ofCancer Research in Los Angeles, California. All three posters willbe available on Vion's website, <a target="_blank" href="http://www.vion...
Other TagsConjunctivalVitreousSuturing
(Date:11/18/2008)... Chairman, Tony Strange Appointed to CEO position ... , MELVILLE, N.Y., Nov. 18 /PRNewswire-First... GTIV ), a leading provider of comprehensive home...f Directors has finalized a management succession ...l become the Company,s Chief Executive Officer in ...
(Date:11/18/2008)...echanisms, scientists show , , TUESDAY, ...egulated by different molecular mechanisms, accord...es the long-held belief that itching is a less int...This finding could prove important in improving tr...g Chen, of Washington University,s Pain Center, in...
(Date:11/18/2008)...ed genes and understanding how they work has been ...t Cold Spring Harbor Laboratory (CSHL), five diffe...tise to speed up the rate of discovering cancer-re...g animals. , The result of the collaborative e...tic screen that in a preliminary test succeeded in...
(Date:11/18/2008)...f dangerous side effect , , TUESDAY, No...rug Avastin appears to be associated with a greate...atients with a variety of cancers. , This risk ...cts associated with the drug, including clots in t...tion. , It has previously been recognized that ...
Breaking Medicine News(10 mins):Health News:Gentiva Health Services Confirms Management Succession 2Health News:Gentiva Health Services Confirms Management Succession 3Health News:Gentiva Health Services Confirms Management Succession 4Health News:Itching Not a Less Intense Form of Pain 2Health News:Cold Spring Harbor science teams identify 13 new tumor-suppressor genes in liver cancer 2Health News:Cold Spring Harbor science teams identify 13 new tumor-suppressor genes in liver cancer 3Health News:Cold Spring Harbor science teams identify 13 new tumor-suppressor genes in liver cancer 4Health News:Cancer Drug Ups Risk of Clots in Veins 2Health News:Cancer Drug Ups Risk of Clots in Veins 3
(Date:11/18/2008)...or Scientific Research (NWO) and the Netherlands R...ed forces with colleagues in China to launch a new... Research Programme (JSTP). It is the first time t...loping bilateral cooperation with Chinese ministri...ched the joint research programme during their rec...
(Date:11/17/2008)...national research team has found a new gene associ...RICKLE1 gene mutation was specific to a rare form ...new ideas for overall epilepsy treatment. , The ...ions from six different countries, appear in the N...tics . , In epilepsy, nerve cells in the brain s...
(Date:11/17/2008)...cognized climate scientist and economist Jae Edmon...f carbon capture and sequestration in climate stab...h International Conference on Greenhouse Gas Techn...th the Department of Energy,s Pacific Northwest Na...d insights to the greenhouse gas and carbon manage...
(Date:11/17/2008)...eposition associated with industry and agriculture...tion, reducing plant growth and polluting surface ...in Nature Geoscience . , The study, conducted in... of Colorado, University of Montana, Slovak Academ...ws what can happen when nitrogen deposition in any...
Breaking Biology News(10 mins):NWO and Academy launch research program with China 2International team discovers gene associated with epilepsy 2PNNL leadership in carbon sequestration featured at international conference 2Acid soils in Slovakia tell somber tale 2Care Improvement Plus Launches 2009 Benefits in Missouri 27763 1Care Improvement Plus Launches 2009 Benefits in Missouri 27763 2Nanoemulsion Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen 27760 1Nanoemulsion Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen 27760 2Phase 3 Data Indicate Investigational 13 valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 27756 1Phase 3 Data Indicate Investigational 13 valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 27756 2Phase 3 Data Indicate Investigational 13 valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 27756 3Phase 3 Data Indicate Investigational 13 valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 27756 4Phase 3 Data Indicate Investigational 13 valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 27756 5Phase 3 Data Indicate Investigational 13 valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 27756 6Phase 3 Data Indicate Investigational 13 valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 27756 7NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy 3349 1NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy 3349 2NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy 3349 3
Other Contentsfeverfeverfeverfeverfeverfeverfeverfeveryellowyellowyellowyellowyellowyellowyellowyellowsystemsystemsystemsystemsystemsystemsystemsystemsystemsystemvestibularvestibularstomatitisstomatitisvesicularvesicularvirologyvirologyvirologyclassificationclassificationclassificationclassificationclassificationclassification